Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (NCT02446405)

🧪 Interventions in This Study

• Enzalutamide (DRUG)
• NSAA (DRUG)
• LHRHA or Surgical Castration (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (82 Sites)

Showing the first 25 of 82 sites.

• Dana Farber Cancer Institute — Boston, Massachusetts
• Chris O'Brien Lifehouse — Camperdown, New South Wales
• Coffs Harbour Health Campus — Coffs Harbour, New South Wales
• Concord Cancer Centre - Concord Repatriation General Hospital — Concord, New South Wales
• St Vincent's Hospital Sydney — Darlinghurst, New South Wales
• Nepean Cancer Care Centre — Kingswood, New South Wales
• St. George Hospital — Kogarah, New South Wales
• Central West Cancer Services — Orange, New South Wales
• Port Macquarie Base Hospital — Port Macquarie, New South Wales
• Prince of Wales Hospital — Randwick, New South Wales
• Genesis Care North Shore — St Leonards, New South Wales
• Tamworth Rural Referral Hospital — Tamworth, New South Wales
• The Tweed Hospital — Tweed Heads, New South Wales
• Riverina Cancer Care Centre — Wagga Wagga, New South Wales
• Sydney Adventist Hospital — Wahroonga, New South Wales
• Wollongong Hospital — Wollongong, New South Wales
• Royal Darwin Hospital — Tiwi, Northern Territory
• Sunshine Coast University Hospital — Birtinya, Queensland
• Townsville Hospital — Douglas, Queensland
• Royal Brisbane and Women's Hospital — Herston, Queensland
• Gold Coast University Hospital — Southport, Queensland
• Princess Alexandra Hospital — Woolloongabba, Queensland
• Royal Adelaide Hospital — Adelaide, South Australia
• Flinders Medical Centre — Bedford Park, South Australia
• Adelaide Cancer Centre - Ashford Cancer Care Centre — Kurralta Park, South Australia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostatic Neoplasms

• A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer — Phoenix, Arizona
• PSMA PET/CT for Assessment of Recurrent Prostate Cancer — Vancouver, British Columbia
• An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS — Homewood, Alabama
• A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer — Los Angeles, California
• Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy — Fort-de-France,
• A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer — Birmingham, Alabama

Explore by condition: All Prostatic Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.